UBE2F-SAG–Mediated RHEB Neddylation: Mechanistic Insights into mTORC1 Activation and Liver Tumorigenesis

Study Background and Research Question

Neddylation, the covalent attachment of the ubiquitin-like molecule NEDD8 to target proteins, has emerged as a critical post-translational modification (PTM) regulating protein stability, localization, and function in health and disease. While the role of cullin neddylation in cell cycle and proteostasis is well established, the specific substrates and consequences of neddylation in non-cullin proteins, particularly in the context of tumorigenesis, are less understood. The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth and metabolism, frequently hyperactivated in hepatocellular carcinoma (HCC). RHEB, a small GTPase, is the canonical activator of mTORC1, but how PTMs like neddylation modulate RHEB function remained unclear. The central question addressed by this study is whether RHEB is subject to neddylation, and if so, how this modification influences mTORC1 activity and liver cancer progression.

Key Innovation from the Reference Study

The landmark finding of this research is the identification of RHEB as a bona fide neddylation substrate, modified at lysine 169 by the UBE2F-SAG enzymatic axis. This discovery establishes a direct molecular link between the neddylation machinery and the activation of the mTORC1 pathway in liver cells. Mechanistically, UBE2F (NEDD8 E2 conjugating enzyme) and its E3 partner SAG promote RHEB neddylation, which enhances RHEB's lysosomal localization and GTP-binding affinity—two properties essential for robust mTORC1 activation. This innovation expands the functional repertoire of neddylation beyond cullin family proteins and positions the UBE2F-SAG–RHEB axis as a critical regulator of tumor-promoting signaling in the liver.

Methods and Experimental Design Insights

The authors combined genetic, biochemical, and in vivo approaches to dissect the role of RHEB neddylation. In cultured cells, CRISPR/Cas9-mediated depletion of UBE2F was employed to assess effects on mTORC1 signaling, cell cycle progression, growth, and autophagy. Immunoprecipitation and mass spectrometry pinpointed K169 as the critical neddylation site on RHEB. The study further utilized liver-specific Ube2f knockout mice crossed with Pten-deficient models to interrogate the physiological consequences of UBE2F loss in liver steatosis and tumorigenesis. Patient-derived HCC samples were analyzed for UBE2F expression and mTORC1 activity to correlate molecular findings with clinical outcomes. Notably, the workflow involved robust protein purification and detection protocols to confirm RHEB’s modification status and interacting partners, illustrating the importance of precise affinity tag strategies and epitope detection in PTM research.

Protocol Parameters

• UBE2F depletion: Achieved via CRISPR/Cas9 or shRNA; assess mTORC1 activity (S6K1/4EBP1 phosphorylation) 48–72 h post-transfection.
• Detection of neddylated RHEB: Immunoprecipitation using anti-RHEB or affinity-purified tag antibody, followed by immunoblotting with anti-NEDD8.
• Liver-specific knockout: Cross Ube2f floxed mice with Albumin-Cre; analyze hepatic steatosis/tumorigenesis in Pten-deficient background over 8–24 weeks.
• mTORC1 activity readout: Immunohistochemistry or immunoblot for phosphorylated S6K1 and 4EBP1 in tissue or lysate samples.
• Protein purification for PTM analysis: Use high-affinity N-terminal leader peptide tags and compatible affinity matrices for robust isolation of RHEB and its modified forms.

Core Findings and Why They Matter

The study demonstrates that UBE2F-SAG–dependent neddylation of RHEB is both necessary and sufficient to potentiate mTORC1 signaling. Loss of UBE2F leads to marked reduction in mTORC1 activity, suppression of cell proliferation, and induction of autophagy. In vivo, liver-specific Ube2f deletion in Pten-deficient mice attenuates hepatic steatosis and tumor burden, underscoring the functional relevance of this axis in driving liver tumorigenesis. Analysis of human HCC samples further reveals a positive correlation between UBE2F levels, mTORC1 activity, and poor patient prognosis. Collectively, these results reveal neddylation as a regulatory switch controlling RHEB-mTORC1 signaling and identify UBE2F-SAG as promising targets for intervention in liver cancer and metabolic disease (reference study).

Comparison with Existing Internal Articles

Recent internal thought-leadership resources, such as From Mechanism to Translation: How X-press Tag Peptide Empowers PTM Research, have emphasized the need for advanced protein purification and detection tools in PTM pathway studies. These articles highlight the X-press Tag Peptide as a next-generation N-terminal leader peptide that streamlines affinity purification and epitope tag–based protein detection—capabilities directly relevant to workflows described in the current reference paper. For instance, precise purification and detection of neddylated RHEB or similar substrates can benefit from affinity purification using ProBond resin and Anti-Xpress antibody detection, methods that are increasingly adopted in complex PTM research (internal review). While the internal resources focus on technical workflows and translational opportunities, the reference study provides mechanistic, disease-relevant validation for such approaches.

Limitations and Transferability

While the study establishes a compelling mechanistic link between UBE2F-SAG–driven neddylation and RHEB-mediated mTORC1 activation, several limitations should be noted. First, the findings are primarily contextualized within liver physiology and cancer; whether similar regulatory mechanisms operate in other tissues or disease models remains to be determined. Second, while K169 neddylation is established as critical, the broader landscape of RHEB PTMs and potential interplay with other modifications (e.g., phosphorylation, ubiquitination) warrants further investigation. Finally, translation to therapeutic targeting of the UBE2F-SAG axis will require careful consideration of tissue specificity and possible compensatory mechanisms. Nonetheless, the experimental approaches and affinity purification strategies described are readily transferable to analogous studies of PTM regulation in diverse systems.

Research Support Resources

To reproduce or extend affinity purification and protein detection workflows related to neddylation and mTORC1 signaling, researchers may utilize specialized N-terminal leader peptide tags. The X-press Tag Peptide (SKU A6010) from APExBIO is designed for high-efficiency isolation and detection of recombinant proteins, featuring a polyhistidine sequence, the Xpress epitope, and an enterokinase cleavage site for tag removal. Its compatibility with both Anti-Xpress antibody detection and affinity purification using ProBond resin facilitates robust analysis of PTM-modified proteins—such as neddylated RHEB—in recombinant expression workflows. The peptide offers high solubility in DMSO and water and is supplied at >99% purity. For optimal performance, follow recommended storage and handling protocols. Integrating such tools allows for rigorous experimental dissection of complex signaling and modification pathways in cancer and metabolic disease research.